- primary open angle glaucoma
- ocular hypertension
- age >18 years
- bradycardia
- obstructive pulmonary disease
- hypersensitivity to the drug
This study is designed to evaluate the safety and tolerability of Xalacom in patients with
primary glaucoma
- primary open angle glaucoma
- ocular hypertension
- age >18 years
- bradycardia
- obstructive pulmonary disease
- hypersensitivity to the drug
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy. | |||
Official Title | Non Interventional Study in Slovak Patients With Primary Open Angle Glaucoma and/or Ocular Hypertension Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy Due to Ineffectivity or Intolerance. | |||
Brief Summary | This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma | |||
Detailed Description | according to physicians decision, patients who met inclusion and exclusion criteria and sign the ICD | |||
Study Type | Observational | |||
Study Design | Observational Model: Case-Only Time Perspective: Prospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | Patients >18 years with primary open angle glaucoma or ocular hypertension | |||
Condition | Glaucoma, Open-angle | |||
Intervention | Drug: Xalacom
Xalacom 1 drop into the affected eye daily
|
|||
Study Groups/Cohorts | Xalacom treatment
patients with primary glaucoma
Intervention: Drug: Xalacom
|
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Enrollment | 457 | |||
Completion Date | June 2009 | |||
Primary Completion Date | June 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
|||
Sex/Gender |
|
|||
Ages | 18 Years and older (Adult, Senior) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Slovakia | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00801437 | |||
Other Study ID Numbers | A6641053 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor | Pfizer | |||
Collaborators | Not Provided | |||
Investigators |
|
|||
PRS Account | Pfizer | |||
Verification Date | June 2011 |
Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.
Pfizer Clinical Trials Contact Center
1-800-718-1021